Skip to main content
logo
Fulcrum Therapeutics, Inc. (FULC)
NASDAQ: FULC · Real-Time Price · USD
3.830
-0.020 (-0.52%)
At close: Aug 21, 2026, 4:00 PM EDT
3.829
-0.002 (-0.04%)
After-hours: Aug 21, 2026, 6:33 PM EDT

Fulcrum Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
--802.816.3419.16
Revenue Growth
--2752.05%-55.77%-66.91%117.19%
Cost of Revenue
56.6456.163.3971.876.7869.7
Gross Profit
-56.64-56.116.61-69-70.44-50.54
Selling, General & Admin
30.428.6736.4541.6741.6930.52
Research & Development
-0.4-----
Operating Expenses
3028.6736.4541.6741.6930.52
Operating Income
-86.64-84.77-19.83-110.66-112.13-81.05
Interest & Investment Income
11.059.8912.1713.332.690.21
EBT Excluding Unusual Items
-75.6-74.88-7.66-97.34-109.44-80.85
Merger & Restructuring Charges
-4.32--2.06--0.43-
Pretax Income
-85-74.88-9.73-97.34-109.87-80.85
Net Income
-85-74.88-9.73-97.34-109.87-80.85
Net Income to Common
-85-74.88-9.73-97.34-109.87-80.85
Net Income Growth
------
Shares Outstanding (Basic)
706362614535
Shares Outstanding (Diluted)
706362614535
Shares Change
12.92%2.21%1.10%36.27%27.23%39.47%
EPS (Basic)
-1.21-1.18-0.16-1.59-2.44-2.29
EPS (Diluted)
-1.21-1.18-0.16-1.59-2.44-2.29
EPS Growth
------

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
-66.14-60.38-2.5-91.47-99.01-80.19
Free Cash Flow Per Share
-0.94-0.95-0.04-1.49-2.20-2.27
Gross Margin
--20.77%---263.73%
Operating Margin
---24.79%-3945.24%-1768.12%-422.97%
Profit Margin
---12.16%-3470.05%-1732.43%-421.89%
Free Cash Flow Margin
---3.12%-3261.07%-1561.23%-418.47%
EBITDA
-85.4-83.38-18.24-108.49-109.72-78.54
EBITDA Margin
---22.80%---
D&A For EBITDA
1.251.391.592.172.412.52
EBIT
-86.64-84.77-19.83-110.66-112.13-81.05
EBIT Margin
---24.79%---
SEC Filings: 10-K · 10-Q